Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Phase III Clinical Study Comparing BL-M05D1 for Injection With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN) 18.2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-line Treatment

NCT07518147 is registered in ClinicalTrials.gov with Sichuan Baili Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07518147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07518147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Phase III Clinical Study Comparing BL-M05D1 for Injection With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN) 18.2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-line Treatment
Lead sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
May 15, 2026
Completion date
December 31, 2029
Enrollment
438 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, gastroesophageal junction adenocarcinoma